Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 948M | 695M | 545M | 473M | 440M |
| Gross Profit | 122M | 94M | 67M | 59M | 49M |
| Operating Income | 51M | 38M | 25M | 13M | 5M |
| EBITDA | 61M | 44M | 31M | 18M | 9M |
| Net Income | 30M | 23M | 13M | 7M | 3M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$33.44
-3.30% today
1Y Change
+18.50%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
The Pennant Group, Inc. (PNTG) is a Healthcare stock with a market cap of $1.09B and listed on NASDAQ. The stock last traded around $33.44 and up 18.5% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +36.3%, EPS growth of +19.4%, a dividend yield of 0.0%. What stands out right now is revenue +36.3%, EPS +19.4%, free cash flow -13.2% with operating margin 5.5% and ROIC 4.6%. Valuation already assumes a fairly strong business story at P/E 36.7 and price/sales 1.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PNTG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PNTG
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PNTG Max Drawdown
-26.06%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PNTG and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$439.7M
-7.1% YoY
FY Net Income
$2.7M
-59.4% YoY
Free Cash Flow
-$24.5M
-378.5% YoY
Revenue Growth
+36.3%
EPS Growth
+19.4%
Gross Margin
15.1%
Net Margin
3.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 948M | 695M | 545M | 473M | 440M |
| Gross Profit | 122M | 94M | 67M | 59M | 49M |
| Operating Income | 51M | 38M | 25M | 13M | 5M |
| EBITDA | 61M | 44M | 31M | 18M | 9M |
| Net Income | 30M | 23M | 13M | 7M | 3M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 17M | 24M | 6M | 2M | 5M |
| Total Assets | 968M | 680M | 540M | 512M | 530M |
| Total Liabilities | 594M | 368M | 394M | 386M | 416M |
| Shareholder Equity | 333M | 293M | 140M | 121M | 110M |
| Total Debt | 453M | 273M | 330M | 327M | 355M |
| Net Debt | 436M | 249M | 324M | 324M | 350M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
18M
-301.5% YoY
Capital Expenditures
6M
+55.5% YoY
Free Cash Flow
25M
-378.5% YoY
Key ratios
Gross Margin
15.1%
Operating Margin
5.5%
Net Margin
3.1%
ROE
9.3%
Debt / Equity
1.36x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.